| Similar Articles |
|---|
 |
The Motley Fool
April 24, 2009
Toby Shute |
SunPower, Meet Solar Slump Somewhat out of left field, an earnings miss by the formidable solar power player.   |
The Motley Fool
March 3, 2011
Brian D. Pacampara |
Amylin Pharmaceuticals Shares Plunged: What You Need to Know Shares of Amylin Pharmaceuticals plummeted more than 20% Thursday after its type 2 diabetes drug Bydureon failed to meet primary endpoints in a 26-week study. |
The Motley Fool
October 20, 2011
Travis Hoium |
Amylin Pharmaceuticals Shares Jumped: What You Need to Know Shares of Amylin Pharmaceuticals jumped 11% today after the company released great earnings and pipeline news. |
The Motley Fool
April 15, 2011
Luke Timmerman |
Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug Will this drug be approved in Europe? |
The Motley Fool
April 8, 2009
Toby Shute |
From Solar Contract to Solar Contraction Applied Materials' mystery solar customer comes up short. |
The Motley Fool
April 22, 2009
Selena Maranjian |
Will Health-Care Reform Hurt Investors? The bad news here is that there's quite a bit of uncertainty around this issue, and that some health-care-focused companies may end up suffering. Read on to see who. |
The Motley Fool
March 11, 2009
Toby Shute |
JA Solar Sucks Wind JA Solar's positioning, in the middle of the solar supply chain, doesn't leave much room to widen one's competitive moat over time. |
The Motley Fool
March 20, 2009
Toby Shute |
This Week in Solar Solar news: Energy Conversion Devices slashes its outlook... Canadian Solar announces it took charge in the fourth quarter... Another solar project pipeline consolidation... China Sunergy reports plunging revenue and inventory writedowns... |
The Motley Fool
February 26, 2009
Toby Shute |
First Solar Faces a Freeze Even this thin-film king isn't immune to an industry slump. But the long-term outlook for this firm continues to look pretty fantastic, so why the share-price plunge? |
The Motley Fool
April 7, 2009
Selena Maranjian |
A Quarter Million for Your Doctor If you'd like to set yourself up for a mostly painless retirement, where you're not held hostage by health-care costs, it takes planning. But if you're smart and start early, you can save more than enough to cover all your retirement costs. |
The Motley Fool
May 12, 2010
Matt Koppenheffer |
Are Health-Care Stocks a Buy? Health-care stocks have underperformed the market so far this year. Is it time for a turnaround? |
The Motley Fool
January 28, 2010
Brian Orelli |
The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends. |
The Motley Fool
December 7, 2011
Harsh Chauhan |
A Great Bet in Solar First Solar's dominance could probably see it through the industry turmoil. |
The Motley Fool
September 22, 2010
Brian Orelli |
Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown. |
The Motley Fool
July 25, 2007
Brian Orelli |
On to the FDA With a New Name After four phase 3 clinical trials, Advanced Magnetics is ready to submit a New Drug Application for ferumoxytol, and if all goes well, could have the product on the market by the end of next year. |
The Motley Fool
December 8, 2011
Travis Hoium |
A Better Way to Trade Emerging Industries A long/short strategy may work best in emerging industries. |
The Motley Fool
August 20, 2010
Brian Orelli |
This Billionaire Likes Biotech. Should You? It depends on how much you trust management. |
The Motley Fool
January 23, 2010
Anand Chokkavelu |
Analysts Are Wrong About This Stock Don't be fooled by Wall Street analysts. There are incentives for them to rate a company a "buy" or at the very least a "hold." |
Entrepreneur
April 2008
Scott Bernard Nelson |
Taking Stock How will the economy affect your investments this year? |
The Motley Fool
April 20, 2010
Brian Orelli |
Drug Sales Down! Should We Celebrate? Amylin won't have completed results for a trial comparing Bydureon to Victoza until next year. But until that data is in, it might not be as easy to get the patients back as Amylin is making it out to be. |
The Motley Fool
November 26, 2010
Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool
February 6, 2007
Rick Aristotle Munarriz |
So What, Sohu? The Chinese Internet and wireless content specialist provided a lackluster fourth-quarter report and an equally sleepy outlook for the current quarter. |
The Motley Fool
February 3, 2011
Travis Hoium |
GT Solar Is Seeing Green The solar supplier reported a blowout quarter, but is this as good as it gets? |
The Motley Fool
January 5, 2009
Rick Aristotle Munarriz |
If I Have to Buy 1 Stock in 2009 It's time to invest in the best of the best. After choosing the best stocks in several sectors this analyst chooses China's Sohu as the best of the best. |
The Motley Fool
April 8, 2008
Colleen Paulson |
Invest Where the Jobs Are Think about these growing sectors for your next investing opportunities. |
The Motley Fool
May 19, 2008
Brian Orelli |
What Will Icahn Do With Amylin? Carl Icahn recently took an initial position now worth around $200 million in Amylin Pharmaceuticals, and stockholders must be wondering about his motivation for the purchase. |
The Motley Fool
March 15, 2010
Brian Orelli |
FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it. |
The Motley Fool
May 31, 2011
Brian Orelli |
Pay Attention, Biotech Investors Competitors and partners can't be ignored. |
The Motley Fool
July 8, 2011
Luke Timmerman |
Amylin, Alkermes Once-Weekly Diabetes Drug Passes Heart Trial What does this mean for the drug companies? |
The Motley Fool
July 22, 2010
Brian Orelli |
It's All About the Future for Amylin Its second quarter stank, but there's a lot up ahead. |
The Motley Fool
January 30, 2009
Brian Orelli |
Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%. |
The Motley Fool
March 17, 2011
Brian Orelli |
Taking a Bite Out of Amylin's Obesity Drug Potential Amylin Pharmaceuticals and Takeda announce they were putting a hold on the development of their obesity drug combination pramlintide/metreleptin due to safety issues. |
The Motley Fool
February 28, 2011
David Williamson |
Don't Miss These Health-Care ETFs Two ways ETFs can help your portfolio |
The Motley Fool
September 17, 2007
Zoe Van Schyndel |
Healthy Exchange-Traded Funds Regardless of how much they exercise or how much they spend on plastic surgery, the baby boomers just keep getting older. Therefore, this may be the right time to consider funds focused on the health-care industry. |
The Motley Fool
February 25, 2011
Travis Hoium |
Investors See Clouds Over First Solar First Solar failed to impress investors with fourth-quarter earnings, but they weren't all that bad. |
